Dr. Ramaswamy on Determining Treatment Courses in Metastatic HER2+ Breast Cancer

Bhuvaneswari Ramaswamy, MD, member, Translational Therapeutics Program, section chief, Breast Medical Oncology, The Ohio State University Comprehensive Cancer Center–James, director, Medical Oncology Fellowship Program in Breast Cancer, The Ohio State College of Medicine, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

In general, patients with HER2-positive breast cancer will receive trastuzumab (Herceptin) in combination with pertuzumab (Perjeta) and taxane-based chemotherapy as frontline therapy, says Ramaswamy. Most patients will receive ado-trastuzumab emtansine (T-DM1; Kadcyla) as second-line therapy, Ramaswamy explains. This sequence of therapy is based on the strong overall survival data observed with the regimens in clinical trials, Ramaswamy says.

However, in the third-line and beyond settings, patient factors should be considered to guide treatment selection, says Ramaswamy. For example, a patient with significant central nervous system involvement may be better suited for tucatinib (Tukysa) compared with a patient who has cardiac problems, who could be considered for neratinib (Nerlynx) plus capecitabine, Ramaswamy explains.

Additionally, some patients may not want to take an oral medication, so intravenous options, such as fam-trastuzumab deruxtecan (Enhertu) or margetuximab-cmkb (Margenza) plus chemotherapy, could be considered, says Ramaswamy. Clinical trials could also offer options for patients during any line of treatment to determine whether newer therapies should be included in the therapeutic armamentarium, concludes Ramamswamy.